Interestingly, statin treatment was observed to show antitumorigenic activities against lung cancer by suppressing AKT and the Braf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase 1/2 (ERK1/2) pathways 73-75. This evidence concerns the gene MAP2K7 and lung carcinoma.